~~<i id='1287F24338'><strike id='1287F24338'><tt id='1287F24338'><pre id='1287F24338'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：knowledge 2025-08-25 15:04:43 Page View：98

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Class action alleges UnitedHealth concealed DOJ probe
Next article： Continuity nursing helped my family in our darkest PICU moments

focus

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Empower primary care with adequate payments and technology

PhysicianStormeeWilliamstalkstoanurseandstudentviatheChildren'sHealthTeleHealthSysteminDallas.Childr

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Lessons Learned: This is why you network to find that industry job you want

MollyFergusonforSTATLessonsLearnedisSTATPlus’weeklycolumnoncareersinbiomedicine.Ifyou’rethinkingofju